Yet another genetic/genomic test (this one developed by Metamark Genetics) may have value in the assessment of risk for biochemical progression after first-line surgery for prostate cancer. According to an article by Saad et al. in the Journal of Urology (and as also reported on the MedPage Today web site), it appears that MetaMark has […]![]()
